Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.

Abstract:

INTRODUCTION:Sepsis remains a leading cause of death worldwide. Despite years of extensive research, effective drugs that inhibit the pro-inflammatory effects of lipopolysaccharide (LPS) and improve outcome when added to conventional sepsis treatments are lacking. Eritoran tetrasodium (E5564) is a promising candidate therapy for sepsis belonging to a new class of such drugs which inhibit LPS-induced inflammation by blocking toll-like receptor 4. AREAS COVERED:This review focuses on the rationale for the use of eritoran tetrasodium in sepsis as well as on its pharmacokinetics, pharmacodynamics, efficacy and safety. Preclinical and clinical studies from a MEDLINE/PubMed literature search in August 2010 with the search terms 'eritoran' and 'E5564' are discussed. EXPERT OPINION:Preclinical in vitro and in vivo studies of eritoran tetrasodium indicate it can limit excessive inflammatory mediator release associated with LPS and improve survival in sepsis models. While early clinical results are promising, its efficacy and safety for treating patients with sepsis are currently under investigation. Even if the ongoing Phase III clinical trial enrolling patients with severe sepsis and increased risk of death shows benefit from eritoran, questions remain and confirmatory studies would be necessary to define its clinical usage.

authors

Barochia A,Solomon S,Cui X,Natanson C,Eichacker PQ

doi

10.1517/17425255.2011.558190

subject

Has Abstract

pub_date

2011-04-01 00:00:00

pages

479-94

issue

4

eissn

1742-5255

issn

1744-7607

journal_volume

7

pub_type

杂志文章,评审
  • Efavirenz in the therapy of HIV infection.

    abstract:IMPORTANCE OF THE FIELD:The use of the first generation non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) as a component of first-line antiretroviral therapy has been accepted worldwide. EFV is the only antiretroviral agent currently on the market that has been combined with emtricitabine and tenofovir dis...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425250903483207

    authors: Rakhmanina NY,van den Anker JN

    更新日期:2010-01-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation.

    abstract:INTRODUCTION:The availability of non-vitamin K antagonist oral anti-coagulants alongside vitamin K antagonists has offered a variety of options for anti-coagulation, but has also necessitated a good understanding of the pharmacological properties of each of these drugs prior to their use, to maximise the therapeutic be...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2019.1604686

    authors: Fawzy AM,Lip GYH

    更新日期:2019-05-01 00:00:00

  • Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.

    abstract:INTRODUCTION:Emtricitabine/tenofovir disoproxil fumarate fixed-dose combination (FTC/TDF FDC) is the co-formulation of a nucleoside and a nucleotide, respectively. After oral administration, both drugs exhibit plasma and intracellular half-lives suitable for once-daily dosing. Within the host cells, active metabolites ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2012.714367

    authors: Uglietti A,Zanaboni D,Gnarini M,Maserati R

    更新日期:2012-10-01 00:00:00

  • Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.

    abstract::The in vitro pharmacological profiling of drugs using a large panel of cloned receptors (e.g., G protein-coupled receptors, ligand-gated ion channels, Na(+)-dependent monoamine transporters), an approach that has come to be known as 'receptorome screening', has unveiled novel molecular mechanisms responsible for the a...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.1.3.377

    authors: Setola V,Roth BL

    更新日期:2005-10-01 00:00:00

  • The use of accelerator mass spectrometry to obtain early human ADME/PK data.

    abstract::There is an increasing recognition within the pharmaceutical industry of the importance of the ADME studies in drug registration. Consequently, there has been a drive in recent times to conduct the ADME studies as early as possible in the development programme. There are, however, regulatory barriers, particularly in ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.1.1.23

    authors: Lappin G,Garner RC

    更新日期:2005-06-01 00:00:00

  • Telmisartan in the treatment of hypertension.

    abstract:BACKGROUND:Telmisartan is an orally active angiotensin II receptor antagonist prescribed once daily. OBJECTIVE:To evaluate the efficacy of telmisartan on blood pressure control, and on other end points, when given as monotherapy or in combination. METHODS:Review of published literature. RESULTS:Telmisartan produces ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.4.4.485

    authors: Rosario BH,Hendra TJ

    更新日期:2008-04-01 00:00:00

  • Novel models for assessing blood-brain barrier drug permeation.

    abstract:INTRODUCTION:The blood-brain barrier (BBB) is a selectively permeable micro-vascular unit which prevents many central nervous system (CNS)-targeted compounds from reaching the brain. A significant problem in CNS drug development is the ability to model BBB permeability in a timely, reproducible and cost-effective manne...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2012.677433

    authors: Geldenhuys WJ,Allen DD,Bloomquist JR

    更新日期:2012-06-01 00:00:00

  • Mechanistic biomarkers for cytotoxic acute kidney injury.

    abstract::Acute kidney injury is a common condition and is associated with a high mortality rate. It has been recognised that routinely used measures of renal function, such as levels of blood urea nitrogen and serum creatinine, increase significantly only after substantial kidney injury occurs and then with a time delay. Insen...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2.5.697

    authors: Vaidya VS,Bonventre JV

    更新日期:2006-10-01 00:00:00

  • Fondaparinux in acute coronary syndromes.

    abstract::Antithrombotic therapies form the cornerstone of management of acute coronary syndromes (ACS). An ideal antithrombotic agent should reduce ischemic complications while keeping bleeding events to a minimum. Heparins, both unfractionated and low molecular weight, reduce ischemic outcomes but also significantly increase ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425250903456039

    authors: Chaturvedi V,Karthikeyan G

    更新日期:2009-12-01 00:00:00

  • Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.

    abstract:INTRODUCTION:Mepolizumab is a humanized monoclonal antibody that binds to and inactivates IL-5. It is available as a subcutaneous preparation. The practical application of mepolizumab is as an add-on therapy in the treatment of severe eosinophilic asthma. Areas covered: This article was created from a comprehensive lit...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2017.1406919

    authors: Kallur L,Gonzalez-Estrada A,Eidelman F,Dimov V

    更新日期:2017-12-01 00:00:00

  • Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.

    abstract::In adapting to the challenge to make more informed selection of compounds for development, the pharmaceutical industry is increasingly embracing the application of mechanism-based models and prediction tools for prediction of pharmacokinetic parameters. This review first outlines the concepts and application of the ma...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.3.6.865

    authors: De Buck SS,Mackie CE

    更新日期:2007-12-01 00:00:00

  • In silico models for genotoxicity and drug regulation.

    abstract:INTRODUCTION:Whereas in the past, (Q)SAR methods have been largely used to support the design of new drugs, in the last few decades, there has been a new interest in its applications for the assessment of drug safety. In particular, the ICH M7 guideline has introduced the concept that (Q)SAR predictions for the Ames mu...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章

    doi:10.1080/17425255.2020.1785428

    authors: Benigni R,Bassan A,Pavan M

    更新日期:2020-08-01 00:00:00

  • Alleviation of pain in painful diabetic neuropathy.

    abstract:INTRODUCTION:Painful diabetic neuropathy (PDN) is a disabling pain condition. Its pathomechanism remains unknown, but a sensitization and neuronal hyperexcitabilty have been suggested. Only symptomatic pharmacological pain management treatment is currently available. AREAS COVERED:The origin of PDN is enigmatic, and t...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2016.1184648

    authors: Tajti J,Szok D,Majláth Z,Csáti A,Petrovics-Balog A,Vécsei L

    更新日期:2016-07-01 00:00:00

  • A review of valproate in psychiatric practice.

    abstract::Valproate (2-propylpentanoate) is available as valproic acid, sodium valproate and semisodium valproate. It has actions on dopamine, GABA and glutamate neurotransmission and intracellular signaling. Its main psychiatric use is to treat bipolar disorder. It has been used in other psychiatric disorders, including schizo...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425250902911455

    authors: Haddad PM,Das A,Ashfaq M,Wieck A

    更新日期:2009-05-01 00:00:00

  • Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials.

    abstract:BACKGROUND:A growing body of evidence suggests that everolimus might offer effective immunosuppressive activity together with antiproliferative effects that may address some of the unmet needs in the long-term therapeutic management of the post-transplant patient. OBJECTIVE:To summarize the emerging evidence for emplo...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.4.6.807

    authors: Sánchez-Fructuoso AI

    更新日期:2008-06-01 00:00:00

  • Pharmacokinetic evaluation of capecitabine in breast cancer.

    abstract:INTRODUCTION:Capecitabine , an oral prodrug of 5-fluorouracil (5-FU), is adsorbed in its intact form through the intestine and metabolized to 5-FU in tumour cells. In metastatic breast cancer (MBC), capecitabine is an effective and well-tolerated therapeutic option both in monotherapy and in combination with chemothera...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2013.759939

    authors: Daniele G,Gallo M,Piccirillo MC,Giordano P,D'Alessio A,Del Giudice A,La Porta ML,Perrone F,Normanno N,De Luca A

    更新日期:2013-02-01 00:00:00

  • Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer.

    abstract:INTRODUCTION:Integration of targeted therapy and additional chemotherapy options has improved median overall survival (OS) in patients with unresectable metastatic colorectal cancer (mCRC). Cetuximab and panitumumab are examples of targeted therapies, specifically against the epidermal growth factor receptor (EGFR). Th...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2015.1112787

    authors: Lo L,Patel D,Townsend AR,Price TJ

    更新日期:2015-01-01 00:00:00

  • Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions.

    abstract:INTRODUCTION:A major challenge in transplantation is improving long-term organ transplant and patient survival. Immunosuppressants protect the transplant organ from alloimmune reactions, but sometimes also exhibit limiting side effects. The key to improving long-term outcome following transplantation is the selection o...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2011.544249

    authors: Christians U,Klawitter J,Klawitter J,Brunner N,Schmitz V

    更新日期:2011-02-01 00:00:00

  • Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions?

    abstract:INTRODUCTION:Adverse drug reactions with an immune pathogenesis are a problem in the clinic and an impediment to drug development. T lymphocytes are believed to play a role in the pathogenesis; however, the nature of the drug interaction with immune receptors remains an area of debate. AREAS COVERED:This article revie...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2015.992780

    authors: Sullivan A,Gibson A,Park BK,Naisbitt DJ

    更新日期:2015-03-01 00:00:00

  • The effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ function.

    abstract:INTRODUCTION:Therapeutic hypothermia is being employed clinically due to its neuro-protective benefits. Both critical illness and therapeutic hypothermia significantly affect drug disposition, potentially contributing to drug-therapy and drug-disease interactions. Currently, there is limited information on the known al...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2011.574127

    authors: Zhou J,Poloyac SM

    更新日期:2011-07-01 00:00:00

  • The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.

    abstract:INTRODUCTION:Immunosuppressive drugs have a narrow therapeutic range and large inter-individual response variability. This has prompted pharmacogenetic studies, mostly with regard to their dose-concentration relationships, but also about proteins involved in their pharmacodynamics. Some polymorphisms of genes involved ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2011.570260

    authors: Picard N,Marquet P

    更新日期:2011-06-01 00:00:00

  • Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder.

    abstract:INTRODUCTION:Pregabalin is an alternative compound to SSRIs and SNRIs for the first-line treatment of generalized anxiety disorder (GAD). Areas covered: We describe the pharmacokinetic properties of pregabalin and their implications for the treatment of GAD. A search in the main database sources (Medline, ISI, Web of K...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2017.1281247

    authors: Buoli M,Caldiroli A,Serati M

    更新日期:2017-03-01 00:00:00

  • Vandetanib for the treatment of thyroid cancer: an update.

    abstract:INTRODUCTION:Medullary thyroid carcinoma (MTC) is a rare endocrine malignancy accounting for a significant percentage of thyroid cancer-related fatal events. Traditional treatment modalities used in the other types of thyroid carcinomas have been proved largely ineffective in advanced MTC. Better understanding of the m...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2014.885015

    authors: Karras S,Anagnostis P,Krassas GE

    更新日期:2014-03-01 00:00:00

  • Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.

    abstract:INTRODUCTION:It is widely accepted that current practice of polypharmacy inevitably increases the incidence of drug-drug interactions (DDIs). Serious DDIs are a major liability for new molecular entities entering the pharmaceutical market. Various strategies are employed to avoid problematic compounds for clinical deve...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2015.1013095

    authors: Riley RJ,Wilson CE

    更新日期:2015-04-01 00:00:00

  • The influence of gut microbiota on drug metabolism and toxicity.

    abstract:INTRODUCTION:Gut microbiota plays critical roles in drug metabolism. The variation of gut microbiota contributes to the interindividual differences toward drug therapy including drug-induced toxicity and efficacy. Accordingly, the investigation and elucidation of gut microbial impacts on drug metabolism and toxicity wi...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2016.1121234

    authors: Li H,He J,Jia W

    更新日期:2016-01-01 00:00:00

  • Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.

    abstract:INTRODUCTION:The pharmacokinetic properties of anti-infective drugs are a determinant part of treatment success. Pathogen replication is inhibited if adequate drug levels are achieved in target sites, whereas excessive drug concentrations linked to toxicity are to be avoided. Anti-infective distribution can be predicte...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2015.1037278

    authors: Moss DM,Marzolini C,Rajoli RK,Siccardi M

    更新日期:2015-01-01 00:00:00

  • Role of SLC transporters in toxicity induced by anticancer drugs.

    abstract:INTRODUCTION:. Membrane transporters are integral to the maintenance of cellular integrity of all tissue and cell types. While transporters play an established role in the systemic pharmacokinetics of therapeutic drugs, tissue specific expression of uptake transporters can serve as an initiating mechanism that governs ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1080/17425255.2020.1755253

    authors: Huang KM,Uddin ME,DiGiacomo D,Lustberg MB,Hu S,Sparreboom A

    更新日期:2020-06-01 00:00:00

  • Tailored tools to improve pharmacotherapy in infants.

    abstract:INTRODUCTION:Extensive within-population variability is the essence of neonatal pharmacology. Despite this, infants remain one of the last therapeutic orphans. Together with additional legal initiatives, tailoring of already available tools (modeling, covariates, pharmacovigilance) may significantly improve pharmacothe...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2014.931937

    authors: Allegaert K

    更新日期:2014-08-01 00:00:00

  • Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.

    abstract:INTRODUCTION:Multiple myeloma (MM) patients who relapse, or become refractory to currently available novel agents, have limited treatment options with poor outcomes. The introductions of the newer proteasome inhibitor carfilzomib and the immunomodulatory agent pomalidomide have provided new treatment strategies within ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,评审

    doi:10.1517/17425255.2013.827169

    authors: Gay F,Mina R,Troia R,Bringhen S

    更新日期:2013-11-01 00:00:00

  • Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.

    abstract:OBJECTIVES:A medical need remains for a once-daily insulin with 24-h basal coverage in all patients. We characterize the steady-state (SS) pharmacokinetic/pharmacodynamic properties of insulin degludec (IDeg) versus insulin glargine (IGlar). RESEARCH DESIGN AND METHODS:In this controlled, single-center study, 66 type ...

    journal_title:Expert opinion on drug metabolism & toxicology

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/17425255.2015.1058779

    authors: Heise T,Hövelmann U,Nosek L,Hermanski L,Bøttcher SG,Haahr H

    更新日期:2015-01-01 00:00:00